Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA

Summary

An elevated concentration of the thrombin-antithrombin complex (TAT) has been associated with high mortality rates and poor outcome in ischaemic stroke patients treated with tissue plasminogen activator (t-PA). Moreover, antithrombin drugs have been tested in combination with t-PA in the acute phase of ischaemic stroke to increase treatment efficacy. We aimed to study whether poor outcome associated with TAT among ischaemic stroke patients treated with t-PA could be due to the effects of this complex on recanalisation rates of the middle cerebral artery (MCA) and on haemorrhagic transformation. The TAT levels of 89 patients having a proximal MCA occlusion were measured by ELISA, and the patients were then treated with t-PA. Complete recanalisation was diagnosed by transcranial Doppler (TCD) at 1, 2 and 6 hours post-t-PA infusion and haemorrhagic transformation was identified by computed tomography (CT). Lower levels of TAT were associated with better recanalisation rates at all time-points (1 hour: OR = 24.8 95% CI 1.4–434.8, p = 0.028;2 hours:OR = 6.3 95% CI 1.5–27, p = 0.014; 6 hours: OR = 6.4 95% CI 1.5–26.5, p = 0.011) after adjustment for stroke risk factors. However, no correlation was found between TAT concentration and haemorrhagic transformation. The elevated mortality rates previously observed in patients with high levels of TAT might have been due to revascularisation resistance. Low levels of TAT are not associated with an increase in haemorrhagic complications after t-PA, indicating that the combination of thrombin blockers and t-PA could be a safe and effective treatment for ischaemic stroke in the future.

Keywords

t-PA - thrombolysis - thrombin - Argatroban - plasmin

• References

• 1 The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
• 2 Wahlgren N, Ahmed N, Davalos A. et al. SITSMOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITSMOST): an observational study. Lancet 2007; 369: 275-282.
• 3 Alexandrov AV, Demchuk AM, Felberg RA. et al. High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuous monitored with 2-MHz transcranial Doppler monitoring. Stroke 2000; 31: 610-614.
• 4 Molina CA, Montaner J, Abilleira S. et al. Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study. Stroke 2001; 32: 2821-2827.
• 5 Ribo M, Montaner J, Molina CA. et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 2004; 35: 2123-2127.
• 6 Ribo M, Montaner J, Molina CA. et al. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost 2004; 91: 1146-1151.
• 7 Fernandez-Cadenas I, Molina CA, Alvarez-Sabin J. et al. ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neurosci Lett 2006; 398: 167-171.
• 8 Gonzalez-Conejero R, Fernandez-Cadenas I, Iniesta JA. et al. Proyecto Ictus Research Group Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke 2006; 37: 2288-2293.
• 9 Rosell A, Alvarez-Sabin J, Arenillas JF. et al. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusionweighted image lesion increase in human stroke. Stroke 2005; 36: 1415-1420.
• 10 Montaner J, Molina CA, Monasterio J. et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107: 598-603.
• 11 Castellanos M, Leira R, Serena J. et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004; 35: 1671-1676.
• 12 Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Hemost 2006; 32.
• 13 Yang DT, Flanders MM, Kim H. et al. Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events. Am J Clin Pathol 2006; 126: 411-415.
• 14 Salomon O, Steinberg DM, Koren-Morag N. et al. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111: 4113-4117.
• 15 Santamaría A, Martínez-Rubio A, Mateo J. et al. Homozygosity of the T allele of the 46 C-->T polymorphism in the F12 gene is a risk factor for acute coronary artery disease in the Spanish population. Haematologica 2004; 89: 878-879.
• 16 Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M. et al. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activatorinduced recanalization in ischemic stroke patients. J Thromb Haemost 2007; 05: 1862-1868.
• 17 Tanne D, Macko RF, Lin Y. et al. NINDS rtPA Stroke Study Group. Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke 2006; 37: 1798-1804.
• 18 Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007; 38: 967-973.
• 19 Adams HP, Bendixen BH, Kappelle 3rd LJ. et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke 1993; 24: 35-41.
• 20 Brott TG, Haley EC, Levy DE. et al. Urgent therapy for stroke, part I: pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23: 632-640.
• 21 Demchuk AM, Burgin WS, Christou I. et al. Thrombolysis in Brain Ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke 2001; 32: 89-93.
• 22 Burgin WS, Malkoff M, Demchuk AM. et al. Transcranial Doppler ultrasound criteria for recanalization after thrombolysis for middle cerebral artery stroke. Stroke 2000; 31: 1128-1132.
• 23 Ribo M, Molina CA, Rovira A. et al. Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3– to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke 2005; 36: 602-606.
• 24 Pessin M, del Zoppo G, Estol C. Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol 1990; 13: 271-289.
• 25 Clark RA, Watanabe AT, Bradley WG. et al. Acute hematomas: effects of deoxygenation, hematocrit, and fibrin-clot formation and retraction on T2 shortening. Radiology 1990; 175: 201-206.
• 26 Atlas SW, Mark AS, Grossman RI. et al. Intracranial hemorrhage: gradient-echo MRI imaging at 1.5T—comparison with spin-echo imaging and clinical applications. Radiology 1988; 168: 803-807.
• 27 Hayman LA, Ford JJ, Taber KH. et al. T2 effect of hemoglobin concentration: assessment with in vitro MR spectroscopy. Radiology 1988; 168: 489-491.
• 28 Hayman LA, Taber KH, Ford JJ. et al. Effect of clot formation and retraction on spin-echo MR images of blood: an in vitro study. AJNR Am J Neuroradiol 1989; 10: 1155-1158.
• 29 Gulba DC, Barthels M, Westhoff-Bleck M. et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction: relevance for the success of therapy. Circulation 1991; 83: 937-944.
• 30 Scharfstein JS, Abendschein DR, Eisenberg PR. et al. for the TIMI-5 Investigators. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction: Thrombolysis in Myocardial Infarction. Am J Cardiol 1996; 78: 503-510.
• 31 Ray KK, Morrow DA, Gibson CM. et al. for the ENTIRE-TIMI 23 Study Group. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: an ENTIRE-TIMI 23 Substudy. Eur Heart J 2005; 26: 440-446.
• 32 Yamada K, Tsuji J, Kimura S. et al. Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model. Thromb Res 2003; 109: 55-64.
• 33 Morris DC, Zhang L, Zheng GZ. et al. Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke 2001; 32: 2635-2640.
• 34 Kobayashi S, Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Haemost 1997; 23: 531-534.
• 35 Hosomi N, Naya T, Kohno M. et al. The Japan Standard Stroke Registry Study Group. Efficacy of anti-coagulant treatment with argatroban on cardioembolic stroke. J Neurol 2007; 254: 605-612.
• 36 LaMonte MP, Marshall LN, Wang DZ. et al. ARGIS-1 Investigators. Argatroban anticoagulation in patients with acute ischemic stroke. Stroke. 2004; 35: 1677-1682.
• 37 Sugg RM, Pary JK, Uchino K. et al. Argatroban tPA stroke study: study design and results in the first treated cohort. Arch Neurol 2006; 63: 1057-1062.